Recent Updates
Recently added Catalysts
ATHE Positive Sentiment Score: 70/100

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

Monday, January 29, 2024 2 min read
Key Takeaway: Alterity Therapeutics announced that CEO David Stamler will participate in the ShareCafe Hidden Gems webinar scheduled for February 1-2, 2024. This event aims to generate interest and showcase Alterity's efforts in developing treatments for neurodegenerative diseases, particularly through its lead asset ATH434. The webinar is free to access, and an archived replay will be available afterward. The company's focus reflects its commitment to innovation in addressing serious health concerns in the field of neurodegeneration.

Market Sentiment Analysis

POSITIVE FACTORS

  • Alterity Therapeutics is actively participating in a notable webinar, which can increase visibility.
  • The company's focus on neurodegenerative diseases underscores its commitment to addressing significant health issues.
  • The CEO's participation may enhance investor confidence and interest in the firm's future prospects.

Full Press Release Details

MELBOURNE, Australia and SAN FRANCISCO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the ShareCafe Hidden Gems webinar on the following dates/times:
AUSTRALIA PARTICIPANTS:
Date:    Friday, 2 February 2024
Time:    12:30 p.m. AEDT / 9:30 a.m. AWST
UNITED STATES PARTICIPANTS:
Date:    Thursday, 1 February 2024
Time:    5:30 p.m. PT / 8:30 p.m. ET
To access further details of the event and to register at no cost, please click here, or copy and paste the following link into your internet browser:
https://us02web.zoom.us/webinar/register/WN_Xb_tWO_eR6yXkSyaMmqhrA#/registration
An archived replay will be made available following the event.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s web site at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
we-aualteritytherapeutics@we-worldwide.com
remy.bernarda@iradvisory.com

Tags

Alterity Therapeutics
Multiple System Atrophy

Frequently Asked Questions

What is Alterity Therapeutics focused on?

Alterity Therapeutics develops treatments for neurodegenerative diseases.

When is the webinar hosted by David Stamler?

The webinar is on February 2, 2024, at 12:30 p.m. AEDT.

Where can I register for the webinar?

Register for the webinar at the provided Zoom link.

What is Alterity's lead drug candidate?

The lead drug candidate is ATH434 for treating Parkinsonian disorders.

Is there an archived replay of the event?

Yes, an archived replay will be available after the event.

Tags: ATHE Viatris Investor Conferences Healthcare Alterity Therapeutics neurodegenerative diseases David Stamler ATH434 Hidden Gems webinar
Last updated: Jan 29, 2024